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The microtubule-associated protein tau can associate with
various other proteins in addition to tubulin, including the SH3
domains of Src family tyrosine kinases. Tau is well known to
aggregate to form hyperphosphorylated filamentous deposits in
several neurodegenerative diseases (tauopathies) including
Alzheimer disease. We now report that tau can bind to SH3
domains derived from the p85 subunit of phosphatidylinositol
3-kinase, phospholipase C1, and the N-terminal (but not the
C-terminal) SH3 of Grb2 as well as to the kinases Fyn, cSrc, and
Fgr. However, the short inserts found in neuron-specific iso-
forms of Src prevented the binding of tau. The experimentally
determined binding of tau peptides is well accounted for when
modeled into the peptide binding cleft in the SH3 domain of
Fyn. After phosphorylation in vitro or in transfected cells, tau
showed reduced binding to SH3 domains; no binding was
detected with hyperphosphorylated tau isolated from Alzhei-
mer brain, but SH3 binding was restored by phosphatase treat-
ment. Taumutants with serines and threonines replaced by glu-
tamate, to mimic phosphorylation, showed reduced SH3
binding. These results strongly suggest that tau has a potential
role in cell signaling in addition to its accepted role in cytoskel-
etal assembly, with regulation by phosphorylation that may be
disrupted in the tauopathies including Alzheimer disease.
Tau is the principal microtubule-associated protein found in
axons in the nervous system (1, 2) where it promotes the nucle-
ation, elongation, stabilization, and bundling of microtubules
(3). On cell fractionation tau is also found in non-cytoskeletal
locations, and up to 25% of cellular tau has been reported to be
in membrane fractions (4); it is also reported to be present in
lipid rafts in neurons (5, 6) and oligodendrocytes (7).
Three or four partial repeats of 30–31 amino acids in the
C-terminal half of tau, which show similarities to regions in
MAP2 andMAP4 (8), providemost of themicrotubule-binding
affinity (see Fig. 1), whereas the N-terminal half of tau projects
out frommicrotubules (9). These parts of the molecule may be
involved in binding other proteins or cellular components (10),
and tau has been shown to be able to bind to a variety of other
proteins (for review, see Brandt and Leschik (11)), including a
number that have roles in cell signaling.
Potential signaling proteins shown to bind both to microtu-
bules and tau include protein phosphatases PP1 (12) and PP2A
(13); manipulation of the binding of PP2A to tau affects its
catalytic activity in cells (14). The scaffolding protein 14-3-3
binds to tau and is reported to mediate its binding to glycogen
synthase kinase 3 (GSK3)4 (15), an important tau kinase (16–
19). Tau and arachidonic acid together activate phospholipase
C (PLC) 1 in vitro (20), and PLC1 can bind to tau in brain
extracts (21).
The tyrosine kinases Fyn, cSrc, and Lck have been shown to
bind to tau through their SH3 domains (22). SH3 domains nor-
mally recognize sites on proteins that contain the motif PXXP.
There are seven PXXP motifs in human tau (see Fig. 1B), all of
which include or are very close to known phosphorylation sites.
Furthermore, when Fyn was co-expressed with tau in fibro-
blasts, the tau became phosphorylated on tyrosine residues
(22), and phosphotyrosine-labeled tau has been found in tau
from human fetal and Alzheimer brain (23, 24) as well as in
brain from neonatal mice (25). In oligodendrocytes Fyn activity
was required along with tau to allow process formation (7).
Although tyrosine phosphorylation of tau was discovered
relatively recently, tau has long been known to be a phospho-
protein (26), with phosphorylation distributed over several ser-
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ine and threonine sites (19, 27, 28). Tau isolated from the brains
of fetuses or neonates is more highly phosphorylated than that
from adults. Tau extracted from the brains of patients with
Alzheimer disease (AD) is hyperphosphorylated, with phos-
phates distributed among 39 or more sites (19, 29, 30). Alzhei-
mer tau is polymerized to formpaired helical filaments (PHF) and
straight filaments and aggregates of these filaments form neurofi-
brillary tangles, one of the two principal hallmarks of AD.
Hyperphosphorylated tau (PHF-tau) accumulates in brains
before neurofibrillary tangles appear and is unable to bind
tubulin or to promote microtubule formation or stabilization.
However, when tau is enzymatically phosphorylated in vitro,
for example by the mitogen-activated protein kinase ERK2,
only a modest reduction in microtubule binding is apparent
(31). The greatest effects on microtubule binding are given by
phosphorylation within the microtubule binding repeat
regions, whereas most of the phosphorylation sites are in the
regions flanking the microtubule binding repeats (see Fig. 1B).
Many of the serine and threonine residues that are phosphoryl-
ated both in normal tau and in PHF-tau are followed by prolines
(19, 29, 30). Many of the functions of phosphorylation, there-
fore, are unknown, and it is unclear why so many sites can be
phosphorylated even in normal (especially fetal) tau orwhat the
causes and effects of hyperphosphorylation in the tauopathies
might be.
It has been shown by co-immunoprecipitation that tau is
bound to SH3-containing proteins in extracts from cultured
cells (22, 23) and from brain (21) asmentioned above.We show
here that tau can bind to several SH3-containing signalingmol-
ecules in addition to those already reported and that tau phos-
phorylation can reduce binding. Furthermore, model building
based on extensive structural studies of SH3 domains provided
useful insight into the putativemolecular interactions and basis
for binding to tau.
EXPERIMENTAL PROCEDURES
Plasmids for bacterial expression of human tau, isoforms
0N3R and 2N4R (32), and mutants of 2N4R tau with either one
glutamate (S235E) or 18 glutamates in the N-terminal half of
the molecule (ETau18, here referred to as Tau-E18) (33) were
donated byDr.M. Goedert andDr.M. Smith (MRCLaboratory
of Molecular Biology, Cambridge, UK). Tau-E18 had gluta-
mates at the following positions: 46, 50, 69, 111, 153, 175, 181,
198, 199, 202, 205, 208, 210, 212, 214, 217, 231, and 235 (33).
Tau with 10 glutamates (hTau441Glu10, i.e. based on 2N4R;
referred to in this paper as Tau-Glu10) was donated by Dr. R.
Brandt (University of Osnabru¨ck) (34). Tau-Glu10 had gluta-
mates at positions 198, 199, 202, 231, 235, 396, 404, 409, 413,
and 422 (34) (numbering of the tau sequence is based on the
2N4R isoform of human tau, containing 441 amino acids (32)).
Tau constructs for expressing the N-terminal (1–249) and
C-terminal (250–441) halves of tau (Tau-NT andTau-CT con-
taining, respectively, residues 1–249 and 250–441 of 0N4R tau)
were donated byDr. H. Yanagawa (Keio University, Yokohama,
Japan) (35). The various constructs used are illustrated dia-
grammatically in Fig. 1. All tau derivatives were expressed in
Escherichia coli BL21(DE3) cells and purified as described pre-
viously (36, 37). Post-mortem brains from healthy and AD sub-
jects were supplied by the MRC Neurodegenerative Diseases
Brain Bank, King’s College London Institute of Psychiatry.
PHF-tau (30) and normal control brain tau (36) were purified as
described previously in the presence of phosphatase inhibitors
but omitting the chromatography stages. PHF-Tau was
dephosphorylated by treatment with -phosphatase (NewEng-
land Biolabs, Hitchin, UK) (38).
Constructs for bacterial expression of glutathione S-transfer-
ase (GST) (i.e.pGEX-4T empty vector) and fusion proteinswith
the SH3 domains of chicken cSrc, human Fgr, the p85 regula-
tory subunit of bovine phosphatidylinositol 3-kinase, human
PLC1, and the C-terminal SH3 domain of human p67phox
protein have been described previously (39–43). GST-SH3
constructs of human PLC2 and mouse Fyn were donated by
Dr. S. Watson (Centre for Cardiovascular Sciences, University
of Birmingham) (44) and Dr. S. Anderson (University of Colo-
rado Health Sciences Center, Denver, CO) (45). Dr. I. Gout
(Ludwig Institute for Cancer Research, UCL, London, UK)
donated constructs for expressing neuronal Srcwith inserts of 6
or 17 amino acids (46), which are denoted here as nSrc6 and
nSrc17, and purified GST-SH3 proteins with SH3 domains
fromGrb2 (both N- and C-terminal SH3s), p47phox (N-termi-
nal SH3), and Ras-GTPase-activating protein (Ras-GAP) (39).
Expressed recombinant proteins were purified on glutathione-
Sepharose beads according to themanufacturer’s instructions
(GE Healthcare).
To measure the binding of tau recombinant constructs to
GST fusion proteins, 1–5 l of glutathione-Sepharose beads
FIGURE 1. Tau constructs used and positions of phosphorylation and
pseudophosphorylation sites andproline-rich sequences.A, tau isoforms
and truncation constructs used. The variably spliced N-terminal exons are
shaded (left), and the tubulin-binding partial repeats (1–4) are shaded and
numbered. Repeat 2 is absent in 3R isoforms of tau. B, sites of phosphorylation
determined by chemical or mass spectrometric sequencing (19, 29, 30),
shown by vertical lines; those along the top have been found in PHF-tau, and
those along the bottom have been found in normal adult and/or fetal tau;
adult tau contains many of the same sites found in fetal tau but at lower
stoichiometry (83, 84). Only the 2N4R isoform is shown, but human adult and
PHF-tau consists of amixture of all six isoforms,whereas fetal tau contains the
0N3R isoform. The positions of the four proline-rich regions, containing tau
PXXPmotifs, are shown as thick lines. C, the positions of serine and threonine
residues replaced by glutamates are shown by vertical lines along the top for
Tau-E18 and along the bottom for Tau-Glu10.
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containing 2–10 g of bound recombinant GST fusion protein
were incubated at 4 °Cwithmixing by rotationwith 0.2ml of 10
g/ml tau construct in binding buffer (50mMTris-HCl, pH 7.5,
1 mM EDTA, 0.15 MNaCl, 0.5% (v/v) Triton X-100, 2 mM dithi-
othreitol, 0.5 mg/ml bovine serum albumin, 1% (v/v) protease
inhibitor mixture (Sigma, catalog no. P8849). After 1 h the
beadswere centrifuged for 1min at 1500 g at 4 °C. The super-
natants were discarded, and the beads were washed twice in
0.75 ml of wash buffer (as binding buffer but without protease
inhibitor mixture or serum albumin) and once in 25 mM Tris-
HCl, pH 7.5, 0.1 mM EDTA. Finally, 25 l of 2 Laemmli sam-
ple buffer (47) was added to the beads (which had 10 l of
residual buffer), and the tubes were vortexed and incubated for
5 min at 100 °C before being stored frozen for subsequent gel
electrophoresis and Western blotting. A 5-l sample of the
binding solution (i.e. tau in binding buffer, as was used for incu-
bating with beads as described above) was likewise treated with
25 l of 2 sample buffer, heated, and stored frozen.
For expressing tau inmammalian cells, a V5-His-tagged con-
struct in pcDNA3.1was used as described previously (23). Con-
structs of hemagglutinin (HA)-tagged bovine p85 wild type
and HA-p85-iSH2 in pEF vectors (48) were kindly provided
by Dr. T. Mustelin (Burnham Institute, La Jolla, CA) and green
fluorescent protein-p85wild type (49) was kindly provided by
Dr. W. Gullick (University of Kent). To express GST and GST-
p85-SH3 inmammalian cells, the pCEFL vector (50) was used.
A pCEFL-GST-Net1 construct, kindly provided by Dr. A. Hall
(Sloan-Kettering Memorial Hospital, New York), was used as
template; QuikChangemutagenesis (Stratagene, La Jolla, CA)
was used to construct pCEFL-GST by introducing a stop codon
before the Net1 coding sequence; pCEFL-GST-p85-SH3 was
constructed by insertion mutagenesis, inserting the coding
region of p85 followed by a stop codon that had been gener-
ated by PCR from bovine p85 cDNA.
Chinese hamster ovary (CHO) and COS-7 cells were cul-
tured, transfected, and harvested essentially as described previ-
ously (23). For transfection of CHOcells in 10-cmdishes, a total
of 8 g of DNA was used with 40 l of Lipofectamine Plus
reagent and 25 l of Lipofectamine (Invitrogen). Cells were
washed inTris-buffered saline andharvested in lysis buffer con-
sisting of 25mMTris-HCl, pH 7.5, 10% (v/v) glycerol, 0.5% (v/v)
Triton-X100, 1 mM EDTA, 1 mM EGTA, 1 mM sodium vana-
date, 150 mM NaCl, 10 mM NaF, and “Complete” EDTA-free
protease inhibitors (Roche Applied Science). In some experi-
ments Triton X-100 was replaced with 1% (v/v) Nonidet P40
(Igepal CA630, Sigma). For precipitation of GST or GST fusion
proteins, lysate supernatants (0.6ml) were incubated at 0–4 °C
for 45 min with 5 l of glutathione-Sepharose beads (GE
Healthcare) and then washed, treated, and analyzed as
described above for cosedimenting recombinant proteins.
Peptides linked at their N termini to biotin via an aminohex-
anoic acid linker were synthesized by solid-phase procedures,
purified chromatographically, characterized by both chroma-
tography and mass spectrophotometry, and dissolved at 1
mg/ml in water. They were coupled to streptavidin-agarose
beads (Sigma) by incubating with a 5-fold molar excess of pep-
tide and 2 volumes of binding buffer. After mixing for 30–60
min, excess peptide was removed by washing with 2 0.75 ml
ofwash buffer. For binding to solubleGST-SH3 fusion proteins,
0.2 ml of binding buffer containing 15 g/ml GST-SH3 or GST
was incubated with 2.5 l of peptide-loaded streptavidin beads
for 1 h at 4 °C; the beads were then washed and treated with
sample buffer as described above for glutathione beads. 1 l of
binding solution (GST protein in binding buffer) was added to
29 l of sample buffer and heated and stored frozen as above.
Phosphorylated tau was prepared by incubating 66 g of
2N4R tau with 0.75 g of recombinant GSK3 (New England
Biolabs) in a 50-l reaction containing (final concentrations) 50
mM Tris-HCl, pH 7.5, 1.15 mM EGTA, 0.15 mM EDTA, 3 mM
ATP, 10 mM MgCl2, 5 mM dithiothreitol, 5 M okadaic acid,
0.5% (v/v) protease inhibitor mixture (Sigma). After incubation
for 6 h at 30 °C followed by 5 min at 100 °C, the sample was
cooled and centrifuged, and the supernatant was stored at
20 °C. A control sample, without GSK3, was prepared in
parallel. For binding experiments to glutathione beads contain-
ing bound GST proteins, the buffer used was 40 mM -glycer-
ophosphate, pH 7.6, in place of 50 mM Tris in the binding and
wash buffers.
Denaturing polyacrylamide gel electrophoresis andWestern
blots were performed as described previously (47, 51). The rab-
bit polyclonal anti-tau antibody used in most of the experi-
ments was obtained fromDako Ltd (Ely, UK), whereas antibody
TP007 against the N terminus of tau has been described previ-
ously (51). Anti-GST antibody was fromGEHealthcare. Perox-
idase-conjugated anti-goat antibody was obtained from Santa
CruzBiotechnology (SantaCruz, CA).Western blotswere visu-
alized by enhanced chemiluminescence (ECL) (GEHealthcare).
In some experiments blots were visualized using secondary
antibody coupled to IR800 dye (Rockland Immunochemicals),
and fluorescence was scanned with theOdyssey system (Li-Cor
Biosciences, Cambridge, UK). In Fig. 2 the images for blots or
gels were cut and reassembled to remove unwanted lanes, indi-
cated in the figures by black vertical lines. The panels shown
contained lanes from the same gel or blot except in Fig. 6B
where indicated.
Molecular modeling of peptide/SH3 binding was based on
the peptide ligand interactions of Fyn SH3 in two known struc-
tures: (i) residues 91–104 of the p85 subunit of phosphatidyl-
inositol 3-kinase, bound in the forward (class I) orientation (52)
(Protein Data Bank code 1AZG); (ii) the HIV-1 Nef protein,
bound in the reverse (class II) orientation (53) (Protein Data
Bank code 1AVZ). The sequences of the tau peptide and the
Fyn-SH3 ligand (1AVZ) or the p85 ligand (1AZG) were
aligned and modeled in QuantaTM. A set of alignments was
generated to maximize the match of the proline residues of the
tau peptide to the conserved proline residues of the 1AZG or
1AVZ ligands (to conserve the PXXP pattern). Furthermore, if
an arginine or a lysine were present, then the peptide was
aligned such that the basic residue of the tau peptide matched
with the arginine in the 1AZG or 1AVZ ligands. The spatial
coordinates of the template peptides were then adopted by the
various aligned peptides and modeled (43) to the SH3 domain.
The template peptides were then deleted from the structure to
give a set of template-tau peptide models. Each model was
investigated visually to assess the likelihood of binding, and the
most likely models were subjected to further modeling. To
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check the dynamic behavior of the modeled peptide, the pep-
tide was regularized, and subsequently CHARM minimization
and dynamics were performed.
RESULTS
SH3 Domains from Several Families of Signaling Proteins
Bind to Tau—Fusion proteins of GST linked to SH3 domains
from several proteins were tested for binding to recombinant
2N4R tau in co-sedimentation experiments with glutathione-
Sepharose beads. As shown in Fig. 2A, tau co-sedimentedwith
SH3 domains of cSrc, PLC1, the N-terminal SH3 domain of
Grb2, and most effectively with the p85 regulatory subunit of
phosphatidylinositol 3-kinase. However tau did not associate
with GST itself or with the C-terminal SH3 of Grb2. It also
failed to associate with the neuronal-specific isoforms of Src,
nSrc6 or nSrc17, which have inserts of 6 or 17 amino acids in
their SH3 domains due to alternative splicing (46, 54, 55) (Fig.
2B). The SH3 domain of PLC2 also bound to tau, but the
bindingwasmuchweaker than that of PLC1 (Fig. 2C). In other
experiments (results not shown), tau was found to bind to the
SH3 domain of the Src family kinase Fgr but not to those from
p67phox (C-terminal SH3), p47phox (N-terminal SH3), or Ras-
GAP. Results are summarized in Table 1 along with those
reported by others. The shortest
isoform of tau, 0N3R, also bound to
the SH3 domains of p85, Fyn, and
PLC1 (results not shown).
Locations on Tau of Binding Sites
for SH3 Domains—Tau contains
seven PXXP motifs, which are all in
the N-terminal half of the molecule
(Fig. 1B). Lee et al. (22) showed that
the SH3 domain from Fyn could
bind to a truncated tau protein con-
taining only the N-terminal half of
the molecule but not to one con-
taining only the C-terminal half
based on three-repeat tau. Using the
tau constructs Tau-NT (1–249
based on 0N tau) and Tau-CT
(250–441 based on 4R tau), we con-
firmed that Fyn-SH3 could bind to Tau-NT but not to Tau-CT.
We found also that Tau-NT, but not Tau-CT, was able to bind
to the SH3 domains from p85 and PLC1 and from the Src
family kinases cSrc and Fgr (results not shown).
To demonstrate unequivocally that PXXP motifs in tau are
involved in SH3 binding reactions, peptides corresponding to
each of the four proline-rich sequences were synthesized.
Because the structures and binding properties of SH3 domains
have been extensively described (52, 53), model building was
used to guide in the selection of peptides as well as to predict
possible outcomes of binding experiments.
Four peptides, numbered 1–4 (Fig. 3A), were initially chosen
to span each of these four PXXP-containing regions. Fitting the
peptides to the structure of the Fyn SH3 domain (45, 53) was
attempted with the peptides oriented in either direction, i.e.
class I or class II (56, 57). Results suggested that peptides 1 and
2 were unlikely to bind in either orientation, whereas peptide 3
(which conforms to a classical class II ligand, PXXPXR) and
peptide 4 (which conforms to a classical Class I ligand, RXX-
PXXP) both looked like potential candidates for binding but
only when oriented, respectively, in reverse and forward direc-
tions. The predicted interaction of residues 215–225 of tauwith
the Fyn SH3 are shown in Fig. 4; these are modeled on the
known structure of the HIV-1 Nef protein residues 71–81
bound in class II orientation to the Fyn SH3 domain. Further-
more, it was noted that if peptide 3 (which terminates at Pro-
223) was extended to include Lys-224, then it might interact
with Asp-99 in the Fyn SH3. Therefore, an extended version of
peptide 3 was also synthesized (Peptide 3a). Variants of Peptide
3a were synthesized with Arg-221 replaced by alanine (Peptide
3b) or with prolines 216 and 219 both replaced by alanine, as
these three residues are normally important for interaction of
SH3 domains with class II ligands (57).
The biotinylated peptides shown in Fig. 3A were bound to
streptavidin beads, and the binding ofGST-SH3 fusion proteins
was investigated using co-sedimentation assays (Fig. 3B). GST
itself gave no significant binding to any of the peptides. Strepta-
vidin beads without peptide or when loaded with Peptides 1 or
2 gave no significant binding to any of the fusion proteins.How-
ever, all three SH3 proteins tested (from p85, Fyn, or PLC1)
FIGURE 2. Tau binding to SH3 domains. GST-SH3 fusion proteins, attached to glutathione-Sepharose beads,
were incubated with 2N4R tau, and co-sedimentation of tau was examined by denaturing gel electrophoresis
and Western blotting. Upper panels, blots visualized with Dako anti-tau antibody using ECL; lower panels,
Coomassie Blue staining of gels to demonstrate the presence and loading of the GST proteins. A, tau sedi-
mentedwith SH3domains fromp85, cSrc, PLC1, andGrb2 (N-terminal andC-terminal SH3domains).B, com-
parisonof cSrc-SH3withneuronal-specific isoformswith inserts of 6 or 17 aminoacids.C, comparisonof PLC1,
PLC2, andFynSH3domains.Binding solndenotes the tau-containing solutionused for incubatingwithbeads.
Blot andgel images hadbeen cut and reassembled as shownbyblack vertical lines. Positions ofmolecularmass
markers (M) are shown on the left (kDa).
TABLE 1
Summary of SH3 domains tested for binding to Tau
Protein Binding Reference
cSrc  (22), this work
nSrc6  This work
nSrc17  This work
Fyn  (22), this work
Fgr  This work
Lck  (22)
Abl  (22)
p85  This work
PLC1  This work
PLC2 () This work
Grb2-NSH3  This work
Grb2-CSH3  This work
Crk  (22)
p67phox-CSH3  This work
p47phox-NSH3  This work
Ras-GAP  This work
Spectrin  (22)
Amphiphysin  (7)
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gave detectable binding to Peptide 3, and in each case the bind-
ing was greater to Peptide 3a than to Peptide 3 (i.e. binding was
improved by including lysines 224 and 225). Peptide 4 gave less
binding than Peptide 3 but some binding was detected, partic-
ularly to the p85 SH3. Replacement of prolines 216 and 219 in
Peptide 3a (Peptide 3c) drastically decreased the binding to all
three proteins. Interestingly, replacement of Arg-221 (giving
Peptide 3b) virtually abolished the binding of the SH3s from
p85 and PLC1 but had relatively little effect on binding of the
Fyn SH3; this suggests that lysines 224 and 225 can take over
from Arg-221 in providing a binding partner. These residue
specificities demonstrate that binding was as predicted for the
active site of SH3 domains. This was confirmed by using a syn-
thetic proline-rich peptide derived from p85, residues
83–101, which is a known ligand for several SH3 domains (58);
this blocked the binding of tau to the SH3 domains of p85 and
cSrc in co-sedimentation experiments (results not shown).
Effect of TauPhosphorylation on SH3Binding—The results in
Fig. 3 suggest that the SH3domains fromp85, Fyn, and PLC1
bind to the regions around amino acids 213–221 (contained in
Peptides 3 and 3a) and possibly also 230–236 (contained in
Peptide 4). These regions contain or are very close to several
known phosphorylation sites (19, 29, 30), including the known
GSK3 phosphorylation sites Ser-210, Thr-212, Thr-217, Thr-
220, Thr-231, Ser-235, and Ser-237 (19, 59–61). PHF-tau iso-
lated from AD brain contains phosphorylation sites in these
regions at Ser-210, Thr-212, Ser-214, Thr-217, Thr-231, Ser-
235, Ser-237, and Ser-238 (19, 27, 29, 30, 62).
To investigate whether phosphorylation affects SH3 binding,
tauwas phosphorylated in vitro using recombinantGSK3, and
its binding was determined in GST co-sedimentation assays
(Fig. 5A). The binding of all four SH3 domains tested (fromFyn,
p85, PLC1, and the N-terminal SH3 of Grb2) was consider-
ably decreasedbyphosphorylation.However, the stoichiometry of
phosphorylation byGSK3 in vitro is likely to have been only par-
tial at any given site (also indicated by the presence of more than
one band in the phosphorylated tau sample: Fig. 5A, right panel,
binding soln lane), suggesting that only a partial reduction in bind-
ing would be detected, as was indeed the case.
To avoid problems of partial stoichiometry and uncertainty
of the positions of the modified
amino acids, pseudophosphoryla-
tion mutants were used with gluta-
mate replacing one or more serines
or threonines. Three such mutants
were tested for binding to the SH3
domains from Fyn, p85, and
PLC1 (Fig. 5B). Replacement of
Ser-235 alone by glutamate had lit-
tle effect on tau binding to SH3 (Fig.
5B). In contrast, essentially no bind-
ing was detected for any of these
SH3 domains to Tau-E18; this had
18 glutamates replacing serines and
threonines in the N-terminal half
of the molecule including all the
sites that are followed by proline
and also the known AD sites
Ser-208, Ser-210, and Ser-214. Tau-
Glu10, with 10 glutamates of which
only five are in the N-terminal half
of the molecule (Ser-198, Ser-199,
Ser-202, Thr-231, and Ser-235),
FIGURE 3. Binding of SH3 domains to Tau-derived synthetic peptides.
N-terminally biotinylated peptideswere synthesized as shown inA, with ami-
nohexanoic acid linkers. For peptides 1–4 the PXXP motifs are underlined;
peptides 1–3 each contain two PXXP motifs which share the central proline;
hence, there are seven such motifs in all; for peptides 3b and 3c, the under-
lined residues are those altered from the native sequence present in peptide
3a. B shows Western blots, probed with anti-GST antibody and visualized by
ECL; the peptides used for binding to streptavidin-agarose are shown above
each lane; no peptide was used for the left-most lane. BS, binding solution
containing soluble GST-SH3 protein.M, molecular mass markers.
FIGURE 4. Structure of the SH3 domain of Fyn binding to tau 215–225. The three-dimensional structure of
theFynSH3domainwithboundpeptide fromtheNefproteinofHIV-1 (53) in class II orientationwasusedas the
template for modeling interactions with peptide sequence from tau (see peptides 3 and 3a, Fig. 3). A, the SH3
structure is shown in pink, and the tau peptide is shown in green; the positively charged arginine and lysine are
in blue, and prolines are in yellow. B, a Grasp surface model of the SH3 domain with the red areas representing
the negatively charged surface of the domain, and blue representing the positively charged surface; the tau
peptide is shown in a stick representation.
Phosphorylation Regulates Tau Binding to SH3 Domains
JUNE 27, 2008•VOLUME 283•NUMBER 26 JOURNAL OF BIOLOGICAL CHEMISTRY 18181
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
showed substantially reduced but still significant binding to
p85 and PLC1 but little to Fyn (Fig. 5B). These results are
consistent with the binding of SH3 domains to tau that is not
phosphorylated (or glutamate-substituted) in the regions 213–
221 and 230–236 and that phosphorylation (or glutamate sub-
stitution) within the region 210–220 and at 231 adversely
affects binding. A plausible physiological function, therefore,
for tau phosphorylation in these regions could be the regulation
of binding of other proteins, with tau acting perhaps as a scaf-
fold in cell signaling processes.
Tau from Cells Can Interact with SH3 Domains—To carry
out a signaling role, tau in a cellular environment would need to
be competent to bind to SH3 domains, and this binding would
need to be regulated (inhibited) uponphosphorylation by active
intracellular kinases.
Tauwas isolated fromnormal healthy adult humanbrain and
tested for binding to GST-SH3 fusion proteins by co-sedimen-
tation (Fig. 6A). The SH3 domain from p85 showed good
binding, and longer exposure of the blot showed that the SH3
domains from Fyn and PLC1 could also bind to brain-derived
tau (Fig. 6A, lower panel). Examination of the different protein
bands shows that the most slowly migrating bands gave less
binding, whereas the faster-migrating bands bound preferen-
tially, when compared with tau in the binding solution. This is
consistent with stronger binding being given by less-phospho-
rylated tau components, which would migrate more rapidly.
These results show that endogenous brain tau is competent to
bind SH3 domains, especially p85, and suggest that phospho-
rylation may reduce SH3 binding.
Because PHF-tau isolated from Alzheimer brain is highly
phosphorylated, it might be expected on the basis of the above
results to givemuchweaker binding to SH3 domains. As shown
in Fig. 6B, PHF-tau was found to give scarcely detectable bind-
ing to the SH3 domains from Fyn, p85, or PLC1. However,
after dephosphorylation with -phosphatase, binding was
restored, especially for p85. The “PHF-smear” also showed
binding to all three SH3 domains in addition to the tau mono-
mer bands, although the latter were weak for Fyn and PLC1.
To examine the effects of tau phosphorylation in cells,
COS-7 cells were transfected with tau-V5-His with or without
co-transfection with GSK3. As shown in Fig. 6C, binding to
recombinant GST-p85-SH3 was readily demonstrated (Fig.
6C, second lane), whereas no binding to GSTwas detected (Fig.
6C, first lane). Co-transfection ofGSK3 decreased the amount
of tau that bound to the beads (lane 5), and the decreased
mobility of the tau band demonstrated that intracellular phos-
phorylation had occurred. Similar results were obtained using
CHO cells. These results demonstrate that tau expressed in
mammalian cells can readily bind to p85-SH3, and phospho-
FIGURE 5. Phosphorylation and pseudophosphorylation of tau inhibits
binding to SH3 domains. Cosedimentation analyses were conducted as in Fig.
2.A,GSK3-phosphorylatedtau(rightpanel)orcontrol tau(leftpanel).B,wildtype
tau (top panel) and tau with glutamate replacing serine or threonine residues
(lower three panels). Tau-S235E has glutamate replacing Ser-235, Tau-E18 has 18
replacements of Ser or Thr by glutamate in the N-terminal part of tau, and Tau-
Glu10 has 10 glutamates replacing Ser or Thr, 5 in theN-terminal part of tau and
5 in the C-terminal part-see Fig. 1C.M, molecularmassmarkers.
FIGURE6.SH3bindingof tau frombrainandtransfectedcells.Cosedimen-
tation analyses were performed as in Fig. 2, with development of blots using
ECL in A and C and with infrared fluorescence (Odyssey system) in B. A, tau
isolated from healthy human brain. B, PHF-tau isolated from AD brain (left-
hand five lanes) ordephosphorylatedPHF-tau (next five lanes); thepair of lanes
at the extreme right (from another gel) contain PHF-tau and dephosphoryla-
ted PHF-tau alone (without other components of the binding solutions). An
asteriskmarks a cross-reacting band in the binding solutions, and the upper-
most of the three main bands in PHF-tau comigrated with this nonspecific
band. C, lysates of tau-transfected COS-7 cells that had been co-transfected
with pMT2 (empty vector) or GSK3were incubatedwith glutathione-Sepha-
rose beads containing GST or GST-SH3.
Phosphorylation Regulates Tau Binding to SH3 Domains
18182 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 26•JUNE 27, 2008
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
rylation by endogenous kinases is not sufficient to prevent
binding. Increased intracellular GSK3 activity, however, largely
prevented the binding, demonstrating the feasibility of regulat-
ing the SH3-tau interaction.
DISCUSSION
Although the C-terminal half of tau contains its microtu-
bule-binding sites and is principally responsible for the tau
microtubule-stabilizing properties, the function of the N-ter-
minal half of the molecule was for a long time largely unknown
(63). Tau has been suggested to be involved in cell signaling (see
the Introduction). Phosphorylation of tau weakens its binding
to microtubules and reduces its ability to promote microtubule
assembly (31, 64–66), and hyperphosphorylated PHF-tau iso-
lated from AD brain is essentially unable to enhance microtu-
bule assembly (67); however, the large number of phosphorylat-
able sites (at least 15 in fetal and adult tau (19, 28, 29, 68) and up to
45 in PHF-tau (19, 30)) suggest that individual phosphorylation
sites or groups of sites may have other more specific roles. The
resultspresentedhere strengthen thecase for taubeing involved in
cell signaling in several important respects.
Tau Binds to SH3 Domains from Several Types of Signaling
Protein—Fyn and the related kinases cSrc and Lck have been
shown to bind to tau through their SH3 domains (22). We
found that the SH3 domain of Fgr also binds well to tau but that
SH3 domains from the neuronal-specific Src isoforms nSrc6
and nSrc17 were unable to bind to tau. This suggests that these
neuron-specific isoforms have distinct binding properties and
functions (69).
However, SH3-tau interactions are not confined to Src family
kinases. The interaction between PLC1 and tau, which acti-
vates PLC1 in the presence of arachidonic acid, has been sug-
gested to involve the SH3 domain of PLC1 (20, 21), and we
have now shown experimentally that this is the case. We also
found that the SH3 domain of PLC2 binds only weakly to tau,
consistent with PLC2 being confined to non-neuronal cells.
Furthermore, theSH3domainsofp85 (the regulatory subunit
ofphosphatidylinositol 3-kinase) and theN-terminal SH3ofGrb2,
which are both important proteins for regulating cell growth and
division, bind effectively to tau. This extends, therefore, the reper-
toire of established tau-SH3 interactions,whichnow includes four
important types of signaling molecule. Table 1 summarizes data
from this and earlier studies on SH3 binding to tau.
Studies Based on Structural Modeling Confirm Typical SH3
Interactions—Model building predicted that the sequence con-
taining Peptide 3 would fit well to the SH3 domain of Fyn (Fig.
4). Co-sedimentation studies using immobilized synthetic tau-
derived peptides (Fig. 3) demonstrated that Peptide 3 (contain-
ing the PXXPmotifs at 213–216 and 216–219) did indeed bind
to SH3 domains, and this was enhanced (as predicted by mod-
eling) by extending the peptide to include Lys-224 (Peptide 3a).
Alanine substitution of prolines 216 and 219 drastically
reduced binding, whereas alanine substitution of Arg-221
almost abolished it for all except Fyn, where modeling sug-
gested that lysines 224 and 225may be able to take over the role
of Arg-221. These results showed that the binding has the char-
acteristics expected for peptide interaction with the active site
of SH3 domains.
The deletion analysis of Lee et al. (22) had pointed to 233–
236 as being a Fyn-binding site, but it did not reveal significant
binding to the 213–219 region. Conversely, using synthetic
peptides, we found binding to the 213–219 region but detected
little binding to the 233–236 region. However, our Peptide 4
(Fig. 3), which included PXXP 233–236, was found to bind rel-
atively poorly. Zamora-Leon et al. (70) used a peptide based on
this region but with an extended N terminus that included
lysines 224 and 225, and they successfully demonstrated bind-
ing to the Fyn SH3 in an enzyme-linked immunosorbent assay.
Therefore, our results along with those of Lee et al. (22) and
Zamora-Leon et al. (70) together suggest that both the 213–219
and 233–236 proline-containing regions are likely to be able to
bind the SH3 domains of Fyn. The SH3 domain of p85 showed
rather weak binding to Peptide 4 (containing 233–236) as well
as to Peptide 3 (containing 213–219), whereas the SH3 of
PLC1 binds, at least, to 213–219. The binding to glutamate-
containing “phospho-mutants” (see below) suggests that each
of these three SH3 domains may be able to bind to both 213–
219 and 233–236. It appears, therefore, that SH3 domains that
bind to tau are able to do so by using both 213–219 and 233–
236, and the lysines at 224 and 225 may be important for both,
suggesting mutually exclusive binding. The detailed prefer-
ences differ, however, for different SH3 domains.
Phosphorylation Inhibits Tau-SH3 Interactions—The pres-
ence of phosphorylation sites very close to the PXXP motifs in
tau suggested that phosphorylation might regulate binding
(20). The SH3 of Fyn bound preferentially to a basic component
of tau from neuroblastoma cells (22), and PLC1 bound to a
faster-migrating tau isoform in cell extracts (21); both of these
results are consistent with preferential binding by less-phos-
phorylated forms of tau. In both PC12 cells (4) and SH-SY5Y
cells (71) the tau that bound to plasma membranes was less
phosphorylated than cytoplasmic or total tau. The direct dem-
onstration here that phosphorylation of tau decreases its bind-
ing to SH3 domains establishes the reality of the effects of phos-
phorylation on SH3 binding. The absence of binding to SH3
domains by highly phosphorylated PHF-tau and its restoration
by phosphatase treatment suggests that hyperphosphorylation
could prevent the participation of tau in this aspect of cellular
signaling.
Glutamate-containing phospho-mutants proved in this
study, as in previous ones (4, 33, 34, 72, 73), to be a usefulmodel
of phosphorylation for determining the relevance of different
sites. The lack of effect of the single substitution at Ser-235 is
compatible with the peptide binding experiments of Zamora-
Leon et al. (70), who showed that phosphorylation at Ser-235
had no effect on binding to the SH3 domain of Fyn, whereas in
contrast, phosphorylation at Thr-231 prevented binding.
Therefore, we tentatively interpret our results with Tau-Glu10
as follows; binding in the 231–236 region would be prevented
by the glutamate at 231 (but not by the one at 235), accounting
for the substantial drop in binding in this mutant, whereas the
residual binding that is still found can be attributed to binding
to the 213–219 region, which is unsubstituted. The same effect
was seen qualitatively with the SH3 domains from Fyn, p85,
and PLC1, suggesting that all three are able to bind to each
site, i.e. 233–236 and also 213–219, although to varying extents.
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Phosphorylation at Thr-231 or glutamate substitution of this
residue has been shown to have extensive effects on tau confor-
mation (74), which may contribute to mediating the effects of
modifying this site on SH3 binding. An equivalent threonine in
MAP2c can be phosphorylated, leading to abolition of binding
to Fyn-SH3 (70). Threonines 212 and 217 are also phosphoryl-
ation sites for GSK3 (61), and their phosphorylation may be
responsible for inhibiting SH3 binding to the 213–219 region.
Bhaskar et al. (75), using surface plasmon resonance, found
considerable differences in the binding of Fyn-SH3 to the 3R
and 4R isoforms of tau that were, however, not shown by Src-
SH3. Binding was generally weaker when Thr-231 and Ser-235
were mutated to aspartates; however, replacing Ser-199 and
Ser-202with aspartates caused larger changes, with increases in
affinity of Fyn-SH3 for 4R tau but decreases for 3R tau. This is
unexpected, because the Fyn-SH3-binding sites appear to be
further downstream at residues 213–219 and 230–236 (Fig. 3
andRef. 22). The differences between isoforms and taumutants
were tentatively attributed to conformational effects (75).How-
ever, all the tau forms used in the study by Bhaskar et al. (75)
contained no N-terminal inserts, whereas we used constructs
based on tau 2N4R for investigating the effects of phosphoryl-
ation. We did find, however, that tau 0N3R could bind well to
the SH3 domains of Fyn, p85, and PLC1 (results not shown).
The point mutation R5H (Arg-5 to His, a frontotemporal
dementia mutation) near the N terminus of tau produced con-
siderable changes in binding to Fyn-SH3 (75), and therefore,
the presence ofN-terminal inserts couldwell induce conforma-
tional differences as well. Further work will be needed to
explore the roles of phosphorylation in directly blocking SH3
binding and in mediating changes in binding via possible
changes in conformation, with the latter perhaps being specific
to particular SH3 domains.
Tau from Cells Binds to SH3 Domains and Is Phos-
phorylation-sensitive—It is already known that tau forms co-
immunoprecipitating complexeswith SH3-containing proteins
in cultured cells and brain (21–23). PhospholipaseC1 could be
co-immunoprecipitated with tau from rat brain extracts (21),
and Fyn was co-immunoprecipitated with tau from extracts of
SH-SY5Y neuroblastoma cells (22). Both Fyn and cSrc could be
co-immunoprecipitated with tau when co-expressed in CHO
cells (23). The potential binding, therefore, of tau to SH3
domains in cells and brain tissue is already well established.We
wished to confirm that binding is indeed to SH3domains and to
determine whether phosphorylation of tau regulates this bind-
ing in vivo. We showed that tau in lysates from transfected cells
is able to bind to the SH3 domain of p85 and that intracellular
phosphorylation reduced this effect (Fig. 6C). We also showed
that tau isolated from normal human brain is able to bind SH3
domains (Fig. 6A), whereas PHF-tau from Alzheimer brain is
not (Fig. 6B). Therefore, tau expressed in mammalian cells has
the properties required to bind intracellularly to SH3 domains
in a regulated manner. Experiments that attempted to demon-
strate co-sedimentation of GST-p85-SH3 and tau, when both
had been co-expressed in CHO cells, gave faint tau bands in
some experiments but not in others, and co-immunoprecipita-
tion of tau with p85 was also attempted unsuccessfully. This
may be for methodological reasons; we observed that glutathi-
one beads bound several endogenous cellular proteins and that
capture of transfected GST proteins was only partial. Another
possibility is thatmuch of the cellular taumay be sequestered in
the cell, e.g. by binding to microtubules or membranes, but is
released on lysing the cells.
The reduction in binding to SH3 domains when tau is phos-
phorylated suggests that phosphorylation could participate in a
signaling role that tau may have. It has long been noted that
many of the serine and threonine phosphorylation sites in tau
are followed by prolines (68). It now seems that in some cases it
is the prolines that may possess the primary function (as key
components of bindingmotifs) and that a function of phospho-
rylation at nearby residues may be to regulate this binding.
Phosphorylation of tau alters its binding to other proteins
too. Tau has two binding sites for the scaffolding protein 14-3-
3, one in the microtubule binding region and a stronger one
that is dependent on phosphorylation of tau on Ser-214 (see
Ref. 76). Glutamate-containing phospho-mutants of tau
showed markedly decreased binding to PP2A and to cell mem-
branes (34, 72). In contrast, the WW domain of the prolyl
isomerase Pin-1 binds to the 231–236 region of tau only when
Thr-231 is phosphorylated (77, 78). Therefore, the same pro-
line-rich region of tau can bind one protein when phosphoryl-
ated and others when not phosphorylated.
The results presented here show that tau has the potential for
a broad role in cell signaling through binding to several impor-
tant signaling molecules in a manner that is regulated by phos-
phorylation. Tau and Fyn are emerging, too, as mediators of
neurotoxicity caused by amyloid  peptide (79, 80), with both
being recruited to lipid rafts on exposure of neurons to amyloid
 (6). This may involve excitotoxicity (80) or by stimulation of
N-methyl-D-aspartate receptors (81); in the latter study N-ter-
minal regions of tau were implicated. Complexes involving
N-methyl-D-aspartate receptors, Fyn and PSD-95 that include
tau have been suggested (82). Further experiments are needed
to show whether tau signaling, tau-SH3 binding, and abnormal
phosphorylation are involved in neurotoxic signaling and the
development of AD pathology as well as in tau normal physio-
logical function.
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